Unlike SGLT2i, which can now be administered despite diabetic status in HF and CKD patients with albuminuria, GLP1-RA, which has a more significant influence on glycaemic control, can currently be prescribed in T2DM and/or obese patients only. Here, GLP1R is linked to chronic kidney disease.